By Fineline Cube 
US-based ophthalmic pharmaceutical company Harrow (NASDAQ: HROW) announced a licensing agreement with Taiwan-based Formosa Pharmaceuticals (TPE: 6838), securing exclusive commercialization rights to Byqlovi (clobetasol propionate ophthalmic suspension) 0.05% in the United States.
Byqlovi: A Best-in-Class Ophthalmic Corticosteroid
Byqlovi is a high-potency ophthalmic corticosteroid indicated for managing postoperative ocular inflammation and pain. The drug leverages Formosa’s proprietary APNT nanoparticle formulation technology, ensuring a highly uniform suspension with minimized particle sedimentation and consistent dosing accuracy. This advanced formulation and optimized pharmacological profile position Byqlovi as a leading therapeutic option for postoperative care.-Fineline Info & Tech